---
layout: default
title: Titanium Dioxide
parent: Model Prediction Only (L5)
nav_order: 1234
evidence_level: L5
indication_count: 10
---

# Titanium Dioxide
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Titanium Dioxide: From UV Filter and Pigment to Drug-Induced Osteoporosis

## One-Sentence Summary

Titanium dioxide is an inert pigment, opacifier and UV filter, marketed in the US mainly in sunscreens and cosmetics.
The TxGNN model predicts it may be effective for **drug-induced osteoporosis**, but this rests on the model score alone, with **0 clinical trials** and **0 publications** supporting the indication.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not stated in the license records (products are sunscreens, cosmetics and a homeopathic pellet) |
| Predicted New Indication | Drug-induced osteoporosis |
| TxGNN Prediction Score | 99.9998% |
| Evidence Level | L5 (model prediction only) |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Titanium dioxide is used as a pigment, opacifier and UV filter, not as a drug that acts on a biological target. No pharmacological pathway links it to bone loss.

The high TxGNN score (~1.0) reflects proximity in the knowledge graph, not biological evidence. Titanium is widely used in bone implants, but that is a property of the material and not a pharmacological effect on bone loss. The prediction is therefore **not mechanistically supported** by the available data.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## US Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| M020 | Kiehls Since 1851 Dermatologist Solutions SuperFluid UV Mineral Defense Broad Spectrum SPF 50 Plus Sunscreen | Lotion | Not stated in record |
| M020 | toty Ilumina CC Creamy Compact 3W | Cream | Not stated in record |
| Not listed | Titanium metallicum (Boiron) | Pellet | Not stated in record |
| M020 | bareMinerals ORIGINAL Liquid Mineral Foundation Broad Spectrum SPF 20 Sunscreen | Liquid | Not stated in record |
| M020 | Cover Creme (Baxter of California) | Cream | Not stated in record |

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction has no trials, no literature and no plausible mechanism, so it is a graph-proximity signal only (L5). The drug's real uses (sunscreen, cosmetic pigment) are unrelated to bone metabolism.

The other top predictions do not change this. Most are cataract or diabetic eye terms with no supporting data, and their near-identical scores likely come from shared graph neighbors rather than independent signals. The only literature found (for diabetic retinopathy) covers analytical methods and imaging, not treatment.

**To proceed, the following is needed:**
- Mechanism of action data (DrugBank) and a biological rationale linking titanium dioxide to bone loss
- Preclinical evidence (in vitro or animal bone models) for drug-induced osteoporosis
- Package insert warnings and contraindications, which are currently missing and block safety screening
- Nanoparticle safety assessment before any therapeutic hypothesis
- Route compatibility analysis: current products are topical or other non-systemic forms, and no route suitable for a bone indication has been identified
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

